

【公報種別】特許法第17条の2の規定による補正の掲載

【部門区分】第3部門第2区分

【発行日】平成21年12月17日(2009.12.17)

【公表番号】特表2009-513658(P2009-513658A)

【公表日】平成21年4月2日(2009.4.2)

【年通号数】公開・登録公報2009-013

【出願番号】特願2008-537932(P2008-537932)

【国際特許分類】

C 07 D 495/04	(2006.01)
A 61 K 45/00	(2006.01)
A 61 K 45/06	(2006.01)
A 61 P 3/04	(2006.01)
A 61 P 3/10	(2006.01)
A 61 P 25/24	(2006.01)
A 61 P 25/22	(2006.01)
A 61 K 31/519	(2006.01)
A 61 K 31/5377	(2006.01)
A 61 K 31/551	(2006.01)
C 07 H 15/26	(2006.01)
A 61 K 31/7042	(2006.01)
A 61 K 31/661	(2006.01)

【F I】

C 07 D 495/04	1 0 5
A 61 K 45/00	
A 61 K 45/06	
A 61 P 3/04	
A 61 P 3/10	
A 61 P 25/24	
A 61 P 25/22	
A 61 K 31/519	
A 61 K 31/5377	
A 61 K 31/551	
C 07 H 15/26	C S P
A 61 K 31/7042	
A 61 K 31/661	

【手続補正書】

【提出日】平成21年10月26日(2009.10.26)

【手続補正1】

【補正対象書類名】特許請求の範囲

【補正対象項目名】全文

【補正方法】変更


【補正の内容】

【特許請求の範囲】

【請求項1】

式I:

【化1】



I

[式中、

R¹は独立して、水素、ハロゲン、C₁ - C₈アルキル、C₃ - C₁₀シクロアルキル、フェニル、ナフチル、CF₃、CN、NR⁷R⁷、OR⁶およびSR⁶からなる群より選択され、その中で、少なくとも一つのR¹は水素であり、かつ少なくとも一つのR¹はC₁およびC₁ - C₈アルキルから選択され；

R²は、水素およびC₁ - C₈アルキルからなる群より選択され；

R³は独立して、水素およびC₁ - C₈アルキルからなる群より選択され；

R⁴は、G - D² - Z_nであり；

R⁵は、水素、C₁ - C₈アルキルおよびC₁ - C₈アルコキシからなる群より選択され；

mは、0から1の整数であり；

nは、1から2の整数であり；

Gは、Oであり；

D²は、直接結合、C₁ - C₈アルキルおよびC₃ - C₁₀シクロアルキルからなる群より選択され；

Zは、水素、ハロゲン、ヒドロキシル、C₁ - C₈アルコキシ、C₃ - C₁₀シクロアルキル、C₃ - C₁₀シクロアルコキシ、OCOR⁶、OCO NR⁷R⁷、CN、CONR⁷R⁷、OSO₂R⁶、SR⁶、SOR⁶、SO₂R⁶、NR⁷COR⁷、NR⁷CONR⁷R⁷、NR⁷CO₂R⁷、CO₂R⁷、OPO(O R⁶)₂、NR⁷SO₂R⁶およびCOR⁶からなる群より選択され；

R⁶は独立して、C₁ - C₈アルキル、C₃ - C₁₀シクロアルキル、ヘテロ環およびヘテロアリールからなる群より選択され；並びに

R⁷は独立して、水素、C₁ - C₈アルキル、C₃ - C₁₀シクロアルキルおよびヘテロ環からなる群より選択され、その中で、2つのR⁷およびそれらに結合する原子は、4から7原子の環を適宜形成してもよく、

上記の定義において、ヘテロ環は4～7員单環式環構造を示し、それは飽和または不飽和であってもよく、それは炭素原子並びにN、OおよびSから選択される1～4個のヘテロ原子からなり、該NおよびSヘテロ原子は適宜四級化されていてもよく；並びに

ヘテロアリールは、N、OおよびSから選択される1～4個のヘテロ原子を含む5もしくは6員芳香環を示し、それはフェニル、ナフチル、C₃ - C₁₀シクロアルキル、ヘテロアリールまたはヘテロ環式基と縮合していてもよい】


の化合物、またはその医薬的に許容される塩、立体異性体、プロドラッグ（該プロドラッグは、式Iの化合物における一つ以上のヒドロキシル基から形成される、酢酸エステル、ピバル酸エステル、メチル炭酸エステル、安息香酸エステル、アミノ酸エステル、リン酸エステル、リン酸アセタールまたはO-グルコシドである）、もしくは溶媒和物。

【請求項2】


R²が水素であり、少なくとも一つのR³が水素である、請求項1の化合物。

【請求項3】


【化 2 - 1】




,




,




,




,



,










,










,


【化 2 - 2】




【化 2 - 3】




【化 2 - 4】




，




，




，



，









，










，









【化 2 - 5】




【化 2 - 6】










【化 2 - 7】










【化 2 - 8】









【化 2 - 9】




【化 2 - 1 0 】




【化 2 - 1 1 】




【化 2 - 1 2 】




,




,




,




,



,









,










,


【化 2 - 1 3 】




【化 2 - 1 4 】










【化 2 - 1 5 】




【化 2 - 1 6 】




【化 2 - 1 7 】




【化 2 - 1 8 】




,




,




,




,




,



,








,




,


【化 2 - 1 9 】









【化 2 - 2 0 】









【化 2 - 2 1】










【化 2 - 2 2 】




【化 2 - 2 3 】








【化 2 - 2 4 】










【化 2 - 25】




【化 2 - 2 6 】










【化 2 - 27】




【化 2 - 2 8 】




【化 2 - 2 9 】



【化 2 - 3 0 】



【化 2 - 3 1】



からなる群より選択される化合物。

【請求項 4】

少なくとも一つの請求項 1 の化合物 ; および

少なくとも一つの医薬的に許容される希釈剤もしくは担体を含む医薬組成物。

【請求項 5】

少なくとも一つの別の治療剤をさらに含む、請求項 4 の医薬組成物。

【請求項 6】

少なくとも請求項 1 の化合物 ; および

少なくとも一つの別の治療剤を含む医薬組成物であつて、別の治療剤が、請求項 1 の化合物の前、請求項 1 の化合物と同時、または請求項 1 の化合物の後に投与されうる医薬組成物。

【請求項 7】

肥満の治療に有用な薬剤の製造における、単独での、または一つ以上の治療剤と併用した、請求項 1 または 3 の化合物の使用。

【請求項 8】

糖尿病の治療に有用な薬剤の製造における、単独での、または一つ以上の治療剤と併用した、請求項 1 または 3 の化合物の使用。